Sam Brusco, Associate Editor05.10.22
BlueWind Medical, maker of the Renova iStim implantable tibial neuromodulation device under investigation to treat urgency incontinence alone or in combo with urinary urgency and/or frequency, has closed a $64 million Series B funding round.
The round was led by ConvaTec, a company focused on therapies to manage chronic conditions including continence care.
"Proceeds from the financing will be used to support the ramp in our commercial footprint in anticipation of potential FDA marketing clearance for BlueWind Medical's RENOVA iStim implantable neuromodulation device," Dan Lemaitre, chairman and CEO of BlueWind Medical told the press.
Patient enrollment for the company’s OASIS pivotal study was completed in November at 23 centers in the U.S., UK, The Netherlands, and Belgium. Interim safety data showed no adverse events, and the company plans to submit for U.S. Food and Drug Administration (FDA) marketing clearance later this year based on the OASIS pivotal study.
"At ConvaTec, we focus on solutions that improve the lives of those enduring chronic conditions like incontinence. We believe BlueWind Medical's vision for less invasive care with greater customer control will resonate with end-users and providers alike," said Seth Segel, president and COO, Global Continence Care and Home Services Group of ConvaTec.
"The BlueWind team appreciates that ConvaTec and others share our vision in the potential for RENOVA iStim to transform the care of OAB," concluded Lemaitre.
The round was led by ConvaTec, a company focused on therapies to manage chronic conditions including continence care.
"Proceeds from the financing will be used to support the ramp in our commercial footprint in anticipation of potential FDA marketing clearance for BlueWind Medical's RENOVA iStim implantable neuromodulation device," Dan Lemaitre, chairman and CEO of BlueWind Medical told the press.
Patient enrollment for the company’s OASIS pivotal study was completed in November at 23 centers in the U.S., UK, The Netherlands, and Belgium. Interim safety data showed no adverse events, and the company plans to submit for U.S. Food and Drug Administration (FDA) marketing clearance later this year based on the OASIS pivotal study.
"At ConvaTec, we focus on solutions that improve the lives of those enduring chronic conditions like incontinence. We believe BlueWind Medical's vision for less invasive care with greater customer control will resonate with end-users and providers alike," said Seth Segel, president and COO, Global Continence Care and Home Services Group of ConvaTec.
"The BlueWind team appreciates that ConvaTec and others share our vision in the potential for RENOVA iStim to transform the care of OAB," concluded Lemaitre.